2207 |
Invasive Imaging (IVUS, VH-IVUS and OCT): How I Implement to My Practice? |
Gary S. Mintz |
May. 09. 13 |
2206 |
To Closure or Not to Closure(LAA Closure & PFO Closure) |
Horst Sievert |
May. 09. 13 |
2205 |
Counterpoint: Resisting the Bioabsorbable DES "Bandwagon": A Healthy Dose of Skepticism |
David Joel Cohen |
May. 09. 13 |
2204 |
Featured Lecture: The Gold Standard for PCI Will Be Bioabsorbable DES in 5-10 Years |
Ron Waksman |
May. 09. 13 |
2203 |
Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive |
Adnan Kastrati |
May. 09. 13 |
2202 |
Featured Lecture: The Future Is¡¦ New Anti-platelet Agents (Ticagrelor/Prasugrel), Selective Platelet Function Testing, and Patient-specific DAPT Duration (from 3 Months to Indefinite) |
Matthew Price |
May. 09. 13 |
2201 |
Counterpoint: Surgery Should Be the Dominant Therapy in Multi-Vessel Coronary Disease |
David Paul Taggart |
May. 09. 13 |
2200 |
Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM |
Seung-Jung Park |
May. 09. 13 |
2199 |
Counterpoint: Surgical AVR Remains the Procedure-of-Choice for Most AS Patients |
David Paul Taggart |
May. 09. 13 |
2198 |
Featured Lecture: TAVR Is Preferred in ALL High-risk AS Patients |
Alain G. Cribier |
May. 09. 13 |